1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Drugs In Development, 2022, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, Preclinical and Unknown stages are 12, 6, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 4 molecules, respectively.
Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hairy Cell Leukemia - Overview
- Hairy Cell Leukemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hairy Cell Leukemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hairy Cell Leukemia - Companies Involved in Therapeutics Development
- AbbVie Inc
- Ascentage Pharma Group International
- AstraZeneca Plc
- Autolus Therapeutics Plc
- Bristol-Myers Squibb Co
- Eureka Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Incyte Corp
- Jecho Biopharmaceuticals Co Ltd
- MacroGenics Inc
- Mediolanum farmaceutici SpA
- Mustang Bio Inc
- Novartis AG
- Sorrento Therapeutics Inc
- Wuhan Bio-Raid Biotechnology Co Ltd
- Xi'An Yufan Biotechnology Co Ltd
- Xynomic Pharmaceuticals Holdings Inc
- Hairy Cell Leukemia - Drug Profiles
- abivertinib maleate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- acalabrutinib maleate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- APG-2575 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AUTO-1NG - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CDMO-002 - Drug Profile
- Product Description
- Mechanism Of Action
- cobimetinib fumarate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- dezapelisib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ELB-021 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ET-019002 - Drug Profile
- Product Description
- Mechanism Of Action
- GEM-155 - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Target CD19 for Leukemia or Lymphoma - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Gene Therapy to Target CD19 for Lymphoma and Leukemia - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Target CD19 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Target CD19 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Gene Therapy to Target CD19 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Gene Therapy to Target CD20 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Target CD22 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Target CD22 for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ibrutinib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- interferon alfa-2b - Drug Profile
- Product Description
- Mechanism Of Action
- itacitinib adipate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MB-106 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MGD-024 - Drug Profile
- Product Description
- Mechanism Of Action
- moxetumomab pasudotox - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- obinutuzumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Onureg - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- parsaclisib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vemurafenib - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- XP-102 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Hairy Cell Leukemia - Dormant Projects
- Hairy Cell Leukemia - Discontinued Products
- Hairy Cell Leukemia - Product Development Milestones
- Featured News & Press Releases
- Jul 21, 2021: Study: Ibrutinib effective treatment for difficult to treat forms of hairy cell leukemia
- May 19, 2021: ESMO: BRAF inhibitor and Rituximab for the management of refractory or relapsed HCL
- Dec 10, 2020: CHMP adopts a positive opinion for the medicinal product Lumoxiti for the treatment of relapsed or refractory hairy cell leukaemia
- Jan 02, 2020: The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia
- Dec 08, 2019: Innate Pharma highlights FDA-approved Lumoxiti at ASH 2019
- Nov 07, 2019: Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting
- May 08, 2019: A patient’s 10-year journey to moxetumomab for hairy cell leukemia
- Mar 12, 2019: Innate Pharma announces the appointment of Jennifer Butler appointed as executive vice president, general manager, US
- Nov 27, 2018: AstraZeneca to present on Lumoxiti 2018 American Society of Hematology Annual Meeting
- Nov 02, 2018: Novartis to present data on Dabrafenib and Trametinib combination at 2018 ASH annual meeting
- Sep 17, 2018: AstraZeneca’s Lumoxiti secures FDA nod to treat hairy cell leukaemia
- Jun 02, 2018: Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting
- Apr 03, 2018: US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukaemia
- Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours
- May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Hairy Cell Leukemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hairy Cell Leukemia - Pipeline by AbbVie Inc, 2022
- Hairy Cell Leukemia - Pipeline by Ascentage Pharma Group International, 2022
- Hairy Cell Leukemia - Pipeline by AstraZeneca Plc, 2022
- Hairy Cell Leukemia - Pipeline by Autolus Therapeutics Plc, 2022
- Hairy Cell Leukemia - Pipeline by Bristol-Myers Squibb Co, 2022
- Hairy Cell Leukemia - Pipeline by Eureka Therapeutics Inc, 2022
- Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Hairy Cell Leukemia - Pipeline by Incyte Corp, 2022
- Hairy Cell Leukemia - Pipeline by Jecho Biopharmaceuticals Co Ltd, 2022
- Hairy Cell Leukemia - Pipeline by MacroGenics Inc, 2022
- Hairy Cell Leukemia - Pipeline by Mediolanum farmaceutici SpA, 2022
- Hairy Cell Leukemia - Pipeline by Mustang Bio Inc, 2022
- Hairy Cell Leukemia - Pipeline by Novartis AG, 2022
- Hairy Cell Leukemia - Pipeline by Sorrento Therapeutics Inc, 2022
- Hairy Cell Leukemia - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022
- Hairy Cell Leukemia - Pipeline by Xi'An Yufan Biotechnology Co Ltd, 2022
- Hairy Cell Leukemia - Pipeline by Xynomic Pharmaceuticals Holdings Inc, 2022
- Hairy Cell Leukemia - Dormant Projects, 2022
- Hairy Cell Leukemia - Discontinued Products, 2022
- Number of Products under Development for Hairy Cell Leukemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Ascentage Pharma Group International
- AstraZeneca Plc
- Autolus Therapeutics Plc
- Bristol-Myers Squibb Co
- Eureka Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Incyte Corp
- Jecho Biopharmaceuticals Co Ltd
- MacroGenics Inc
- Mediolanum farmaceutici SpA
- Mustang Bio Inc
- Novartis AG
- Sorrento Therapeutics Inc
- Wuhan Bio-Raid Biotechnology Co Ltd
- Xi'An Yufan Biotechnology Co Ltd
- Xynomic Pharmaceuticals Holdings Inc
